Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:179 (21 January), doi:10.1136/bmj.332.7534.179-a
EditorLiew et al highlight the very small risks associated with precipitating an attack of angle closure glaucoma when dilating a pupil for the purposes of funduscopy.1
The initiating event in acute angle closure glaucoma is incomplete mydriasis (pupil dilatation) resulting in pupil block and the prevention of aqueous drainage through the trabecular meshwork. This partial mydriasis is normally caused by poor ambient lighting conditions, but drugs with adrenergic and anticholinergic properties have also been identified as causative agents. These drugs include ipratropium and tricyclic antidepressants.2 3 Serotonin selective reuptake inhibitors (SSRIs) such as paroxetine and fluoxetine have also been implicated through their anticholinergic properties.4
The British National Formulary advises caution with using these drugs in patients with a history of angle closure glaucoma.5 This is, however, misleading, as patients who have had an attack of angle closure glaucoma will hopefully have been treated with either iridotomies or trabeculectomies and will therefore no longer be at risk. We therefore recommend that all patients taking ipratropium, tricyclics, and SSRIs be warned of the risk of ophthalmic symptoms (painful red eye, blurring of vision, headache, nausea and vomiting), especially those at greater risk (elderly, female, hypermetropic refractive error). This should reduce ocular morbidity in patients who develop this complication.
Peter D Cackett, ophthalmology specialist registrar
Princess Alexandra Eye Pavilion, Edinburgh EH3 9HA pete{at}pdcackett.demon.co.uk
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care